Plasma phosphorylated tau 217 and Aβ42/40 to predict early brain Aβ accumulation in people without cognitive impairment
S Janelidze, NR Barthélemy, G Salvadó… - JAMA …, 2024 - jamanetwork.com
Importance Phase 3 trials of successful antiamyloid therapies in Alzheimer disease (AD)
have demonstrated improved clinical efficacy in people with less severe disease. Plasma
biomarkers will be essential for efficient screening of participants in future primary
prevention clinical trials testing antiamyloid therapies in cognitively unimpaired (CU)
individuals with initially low brain β-amyloid (Aβ) levels who are at high risk of accumulating
Aβ. Objective To investigate if combining plasma biomarkers could be useful in predicting …
have demonstrated improved clinical efficacy in people with less severe disease. Plasma
biomarkers will be essential for efficient screening of participants in future primary
prevention clinical trials testing antiamyloid therapies in cognitively unimpaired (CU)
individuals with initially low brain β-amyloid (Aβ) levels who are at high risk of accumulating
Aβ. Objective To investigate if combining plasma biomarkers could be useful in predicting …
以上显示的是最相近的搜索结果。 查看全部搜索结果